Iron deficiency remains one of the world’s most pressing nutritional challenges, especially for women of reproductive age. Nearly 30 percent of women aged 15-49 are affected. Traditional iron supplements often require high doses and commonly cause gastrointestinal side effects, which can lead to poor adherence.
Enter Probi with a new science-backed approach. Their solution combines the probiotic strain Lactiplantibacillus plantarum 299v (LP299V®) with iron (and in some formulations, vitamin C and folic acid). Clinical trials have shown that LP299V® helps:
- Keep iron in its absorbable form
- Increase the expression of iron-converting enzymes
- Reduce gastrointestinal side effects
- Lower rates of early discontinuation of iron therapy
In 2025, this innovation was honoured across three continents:
- Europe – Probi Female won a prestigious Innovation in Women’s Health Award for combining LP299V® with iron to boost absorption while improving tolerability.
- North America – Women’s Health by Probi: Iron Absorption earned recognition for its novelty and safety, including use in pregnant women.
- Asia – The LP299V + iron formula received the Innovation in Women’s Health award in Bangkok, underscoring its importance for markets with high rates of iron deficiency.
Martina Pettersson, Global Marketing Director at Probi, stated that recognition across Europe, North America, and now Asia in a single year underscores the urgent global need for more effective, better-tolerated iron supplementation. Karen Ong, Head of Asia-Pacific at Probi, emphasized its importance in Asian markets, where iron deficiency remains highly prevalent.
What makes LP299V® promising is that rather than simply increasing iron doses, it enhances how the body uses what it gets. Clinical data show that combining LP299V® with iron reduces gastrointestinal intolerance and lowers early discontinuation of treatment, enabling women to achieve better iron levels more comfortably.
Implications & Takeaways
- For women: better absorption and fewer unpleasant side effects mean higher likelihood of sustained use and improved iron status.
- For healthcare and supplement industry: proves that microbiome-based, tolerance-focused innovations are marketable and valued.
- For global health: in regions with high iron deficiency burden, such solutions may provide more accessible and acceptable iron therapy.
Conclusion
Probi’s award sweep in 2025 marks more than just trophies—it signals shifting expectations in women’s health supplements. Innovations like LP299V® + iron address root challenges (absorption, tolerability) rather than simply pushing higher dosages. As awareness grows, demand will follow for solutions grounded in strong clinical science. This could be a turning point in how iron supplementation is done—and accepted—around the world.
